were realigned to their respective divisions.

The OPQ retitled four of its suboffices and retitled the majority of its divisions. The OPQ will establish the Office of Quality Assurance and within it established the Quality Assurance Staff, Learning and Professional Staff, and the Project Management Staff.

FDA, CDER, OPQ has been restructured as follows:

DCDL. ORGANIZATION. The Office of Pharmaceutical Quality is headed by the Director of Pharmaceutical Quality and includes the following organizational units:

Office of Pharmaceutical Quality (DCDL)
Office of Product Quality Assessment I (DCDLH)
Division of Product Quality Assessment I (DCDLHA)
Division of Product Quality Assessment II (DCDLHB)
Division of Product Quality Assessment III (DCDLHC)
Division of Product Quality Assessment IV (DCDLHD)
Division of Product Quality Assessment V (DCDLHE)
Division of Product Quality Assessment VI (DCDLHF)
Office of Product Quality Assessment II (DCDLB)
Division of Product Quality Assessment VII (DCDLBA)
Division of Product Quality Assessment VIII (DCDLBB)
Division of Product Quality Assessment IX (DCDLBC)
Division of Product Quality Assessment X (DCDLBD)
Division of Product Quality Assessment XI (DCDLBE)
Division of Product Quality Assessment XII (DCDLBF)
Office of Product Quality Assessment III (DCDLA)
Division of Product Quality Assessment XIII (DCDLAA)
Division of Product Quality Assessment XIV (DCDLAB)
Division of Product Quality Assessment XV (DCDLAC)
Division of Product Quality Assessment XVI (DCDLAD)
Division of Product Quality Assessment XVII (DCDLAE)
Division of Product Quality Assessment XVIII (DCDLAF)
Division of Product Quality Assessment XIX (DCDLAG)
Office of Pharmaceutical Manufacturing Assessment (DCDLD)
Division of Pharmaceutical Manufacturing Assessment I (DCDLDA)
Division of Pharmaceutical Manufacturing Assessment II (DCDLDB)
Division of Pharmaceutical Manufacturing Assessment III (DCDLDC)
Division of Pharmaceutical Manufacturing Assessment IV (DCDLDD)
Division of Pharmaceutical Manufacturing Assessment V (DCDLDE)
Division of Pharmaceutical Manufacturing Assessment VI (DCDLDF)
Office of Program and Regulatory Operations (DCDLG)
Division of Regulatory & Business Process Management I (DCDLGA)
Division of Regulatory & Business Process Management II (DCDLGB)
Division of Regulatory & Business Process Management III (DCDLGC)
Division of Regulatory & Business Process Management IV (DCDLGD)
Office of Pharmaceutical Quality Research (DCDLF)
Division of Pharmaceutical Quality Research I (DCDLFA)
Division of Pharmaceutical Quality Research II (DCDLFB)
Division of Pharmaceutical Quality Research III (DCDLFC)
Division of Pharmaceutical Quality Research IV (DCDLFD)
Division of Pharmaceutical Quality Research V (DCDLFE)
Division of Pharmaceutical Quality Research VI (DCDLFF)
Office of Policy for Pharmaceutical Quality (DCDLC)
Compendial Operations and Standards Staff (DCDLCA)
Division of Regulations and Guidance (DCDLCB)
Division of Internal Policy and Communication (DCDLCC)
Division of Editorial and Project Management (DCDLCD)
Office of Quality Assurance (DCDLJ)
Quality Assurance Staff (DCDLJ1)
Learning and Professional Development Staff (DCDLJ2)
Enterprise Project Management Staff (DCDLJ3)
Office of Quality Surveillance (DCDLE)
Division of Quality Intelligence I (DCDLEB)
Division of Quality Intelligence II (DCDLEC)
Division of Quality Intelligence III (DCDLED)
Office of Administrative Operations (DCDLI)
Administrative Analysis Staff (DCDLI1)
Administrative Operations Staff 1 (DCDLI2)
Administrative Operations Staff 2 (DCDLI3)
Administrative Operations Staff 3 (DCDLI4)
Administrative Operations Staff 4 (DCDLI5)
Financial Services Staff (DCDLI6)

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete SMG can find it on FDA's website at: *http://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm.*

(Authority: 44 U.S.C. 3101).

Xavier Becerra,

Secretary of Health and Human Services.

[FR Doc. 2024–01613 Filed 1–26–24; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request

Collection of Grants and Contracts Data the Historically Black Colleges and Universities (HBCUs) and Small Businesses May Be Interested in Pursuing (Office of the Director)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH), Office of the Director, Office of Acquisitions and Logistics Management (OALM), Small Business Program Office (SBPO), has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent

within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Keondra Watts, Program Analyst, NIH, Office of the Director, Office of Acquisitions and Logistics Management, Small Business Program Office, 6701 Rockledge Dr., Bethesda, MD 20892–7786, or call non-toll-free number (301) 443–8722 or Email your request, including your address to: *Keondra.Watts@nih.gov.*

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the **Federal Register** on October 27, 2023, pages 73864–73865 (88 FR 73864) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions and Logistics Management, Small Business Program Office, may not conduct or sponsor, and the respondent is not required to respond to any information collection that has been extended, revised, or implemented on or after January 31, 2024, unless it displays a currently valid Office of Management and Budget (OMB) control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, NIH has submitted to OMB a request for review and approval of the information collection listed below.

Proposed Collection: Collection of Grants and Contracts data the Historically Black Colleges and Universities (HBCUs) and small businesses may be interested in pursuing, 0925–0767, exp., date, 01/31/2024, Office of the Director, Office of Acquisitions and Logistics Management, Small Business Program Office, National Institutes of Health.

Need and Use of Information Collection: Presidential Executive Order 13779 is the White House Initiative to Promote Excellence and Innovation (PEI) of HBCUs. This Executive Order mandates agencies to assist in strengthening HBCUs' ability for equitable participation in federal programs and explore new ways to improve the relationship between the federal government and HBCUs. This initiative will establish how each agency intends to increase the capacity of HBCUs to compete effectively for grants and contracts.

The PEI is a comprehensive plan to increase the capacity of HBCUs as they pursue funding opportunities at the NIH. The PEI provides a platform to increase transparency between HBCUs and the NIH by promoting outreach events and training opportunities and providing technical assistance. Currently, there are six HBCU participants and each selected a minimum of one small business teaming partner to pursue NIH funding opportunities with.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 883.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hour
HBCU Pre-Solicitation Portal for Contracts and Grants (Attachment Number 1).	Private Sector	62	18	45/60	837
Application for Small Business (Attachment Number 5).	Private Sector	43	1	45/60	32
Application for Universities (Attachment Number 4).	Private Sector	19	1	45/60	14
Total		62	1178		883

Dated: January 23, 2024.

Lawrence A. Tabak,

Principal Deputy Director, National Institutes of Health.

[FR Doc. 2024–01698 Filed 1–26–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA–2024–0002]

Final Flood Hazard Determinations

AGENCY: Federal Emergency Management Agency, Department of Homeland Security.

ACTION: Notice.

SUMMARY: Flood hazard determinations, which may include additions or modifications of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or regulatory floodways on the Flood Insurance Rate Maps (FIRMs) and where applicable, in the supporting Flood Insurance Study (FIS) reports have been made final for the communities listed in the table below.

The FIRM and FIS report are the basis of the floodplain management measures that a community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the Federal Emergency Management Agency's (FEMA's) National Flood Insurance Program (NFIP).

DATES: The date of June 6, 2024 has been established for the FIRM and, where applicable, the supporting FIS report showing the new or modified flood hazard information for each community.

ADDRESSES: The FIRM, and if applicable, the FIS report containing the final flood hazard information for each community is available for inspection at the respective Community Map Repository address listed in the tables below and will be available online through the FEMA Map Service Center at *https://msc.fema.gov* by the date indicated above.

FOR FURTHER INFORMATION CONTACT: Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472,